U.S. Markets closed

Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

Kenneth Smith
Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.